Using a cut-off of ≥1.72% CD86+ CLL cells as determined by receiver operating characteristic analysis, we classified this patient cohort into two risk groups and performed a Kaplan–Meier analysis. Here, CD86 is linked to B-cell chronic lymphocytic leukemia.